Morepen Laboratories Ltd

- The company did not provide specific numbers on the current or expected order book during the call. - It was mentioned that detailed data like the number of customers and distributors will be provided in the annual presentation or upcoming quarters. - Strategic moves include reducing low-yield or low-value orders, especially in the API business, focusing on higher-value items. - The company is working on capacity expansion and expects increased production output in upcoming quarters, indicating potential for more orders. - Growth is visible in the medical devices segment and branded formulations, supporting future order inflows. - Company aims to penetrate 3 lakh outlets in Europe over three years but current quarterly progress on this is not quantified. - Overall, expansion plans and new product launches (e.g., Bluetooth glucometer) reflect optimism for growing order inflows.

- Promoters, including the company, want to increase their stake, but no confirmed plans yet. - Fundraising will be needed to achieve the INR5,000 crore top line target in the next five years due to increased working capital and capex requirements. - Strategic decisions on fundraising are still underway; a clear direction is expected in the next two quarters. - The recent QIP was just the beginning (unlocking value); further market approaches will be made to unlock value from the medical devices and consumer businesses. - No specific mentions of immediate new debt or equity issuance apart from the ongoing completion of QIP fund utilization. - Regulatory and strategic approvals are pending for certain structural changes (e.g., medical devices business demerger), which may impact future capital raising. In summary, fundraising plans exist but are not finalized. More clarity is expected soon.

- Morepen Laboratories has ongoing expansion plans funded by a recent QIP with INR123 crores allocated for capex. - Expansion includes three production blocks (P8, P9, P10) with civil and machinery work underway; P8 nearing completion. - API capacity is being increased from 400 KL to 600 KL, with 50 KL already implemented and 15% production increase expected soon. - Finished dosage facility in Baddi is commissioned, capable of 1.2 billion dosages, with validations in process to start booking orders within 12-18 months. - Focus on expanding medical devices segment with new products like nebulizers and ortho support, and plans to unlock value in medical devices and branded formulations. - QIP proceeds utilized for capex, working capital, and ongoing investments; INR137 crores still available as of Sept 30, 2024. - The strategic shift aims to reposition Morepen from a B2B to a more consumer-facing B2C company for better returns and brand value.

- Targeting INR 5,000 crores revenue by 2030 with ~20% CAGR (currently achieving ~18.9% CAGR). - Medical devices expected to grow faster than pharma, shifting revenue mix to about 40% devices and 60% pharma by 2030. - Focus on profitable growth by reducing low-yielding domestic API business and expanding high-value items. - Pharmaceutical exports growing robustly, with Europe up 60% and US up 5%; domestic market reduced to maintain margins. - Medical devices installed base increased from 10.5 million to 13 million meters yearly; strip consumption per meter is rising. - Capacity expansions underway in API (from 400 KL to 600 KL) and formulations to support growth. - New product launches planned in devices (e.g., Bluetooth meters) and medical devices expansion including nebulizers and ortho support. - Expect stronger growth in H2 compared to H1 FY25, with improved capacities now stabilizing.

- EBITDA margin improving: From 6% in FY23 to 11.55% in H1 FY25, targeting 15% in next 3 years and 17-18% in 5 years. - PAT growth strong: Half-year PAT at INR71 crores, TTM PAT at INR132 crores, indicating solid profitability. - EPS rising: TTM EPS around INR2.53 with consistent quarterly EPS of ~65 paise. - Revenue strategy: Focusing on profitable growth over topline; CAGR target of ~20% to achieve INR5,000 crores by 2030. - Diversification: Medical devices expected to grow faster than pharma, aiming for 40:60 revenue split by 2030. - Sustained EBITDA: Consecutive four quarters averaging INR50 crores EBITDA, indicating stable operating earnings. - Margin stability: Confident to maintain or improve margins in FY25 and beyond with product mix improvements. Overall, Morepen aims for steady profit margin expansion, EPS growth, and profitable scale-up by focusing on high-margin segments and expanding capacities.